Search research articles
Contact Us
Filters
Showing results (411-420 of 468) with videos related to
Page
of 47
Sort By:
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Nobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Andre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
Cancer Research
|
October 20, 2021
A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Feng Xu, Man Tong, Cindy S W Tong, et al.
Lancet (London, England)
|
July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Neurology
|
August 10, 2012
Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features
Sharon J Sha, Leonel T Takada, Katherine P Rankin, et al.
Environmental Science and Pollution Research International
|
July 26, 2012
Gender-specific modulation of immune system complement gene expression in marine medaka Oryzias melastigma following dietary exposure of BDE-47
Roy R Ye, Elva N Y Lei, Michael H W Lam, et al.
Future Oncology (London, England)
|
June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|
March 3, 2018
Genetic basis of channelopathies and cardiomyopathies in Hong Kong Chinese patients: a 10-year regional laboratory experience
C M Mak, S Pl Chen, N S Mok, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Page
of 47
Search research articles
Search
Showing results (411-420 of 468) with videos related to
Sort By:
Page
of 47
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Nobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Andre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
Cancer Research
|
October 20, 2021
A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
Feng Xu, Man Tong, Cindy S W Tong, et al.
Lancet (London, England)
|
July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Neurology
|
August 10, 2012
Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features
Sharon J Sha, Leonel T Takada, Katherine P Rankin, et al.
Environmental Science and Pollution Research International
|
July 26, 2012
Gender-specific modulation of immune system complement gene expression in marine medaka Oryzias melastigma following dietary exposure of BDE-47
Roy R Ye, Elva N Y Lei, Michael H W Lam, et al.
Future Oncology (London, England)
|
June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|
March 3, 2018
Genetic basis of channelopathies and cardiomyopathies in Hong Kong Chinese patients: a 10-year regional laboratory experience
C M Mak, S Pl Chen, N S Mok, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Page
of 47